Announcement on Inclusion of Company Products in the National Essential Drug List (2026 Edition)

Chengdu Kanghong Pharmaceutical Group Co., Ltd.·July 9, 2026·3 pages

✨ AI Summary

Chengdu Kanghong Pharmaceutical Group announced that 13 of its main products have been included in the National Essential Drug List (2026 Edition). This inclusion is expected to facilitate promotion in medical institutions and positively impact market expansion. However, future sales performance is uncertain due to various market factors.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 002773 Stock Abbreviation: Kanghong Pharmaceutical

Announcement Number: 2026-042

Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Announcement on Inclusion of Company Products in the National Essential Drug List (2026 Edition)

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false records, misleading statements, or material omissions.

On July 9, 2026, the National Health Commission, the National Administration of Traditional Chinese Medicine, and the National Disease Control Bureau jointly issued the "Notice on Printing and Distributing the National Essential Drug List (2026 Edition)" (Guo Wei Yao Zheng Fa [2026] No. 17). According to statistics, Chengdu Kanghong Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") and its subsidiaries have had 13 of their main products currently on sale included in the "National Essential Drug List (2026 Edition)". The specific situation is as follows:

National Essential Drug List (2026 Edition)

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.